Figure 4 Contribution of both peripheral- and spinal-located
Cav3.2 channels in inflammatory pain
The effect of a systemic administration of ABT-639 (10, 30 or 100 mg/kg,
i.p., C, D ) or intraplantar injection of ABT-639 (2.5 µl in 20
µl, E ) or an intrathecal injection of ABT-639 (10 µg in 5 µl,F ) or their respective vehicles (VEH) were evaluated in the
carrageenan (A , C ) and CFA (D-F ) models. In
all conditions, mice were submitted to the von Frey test to assess
mechanical allodynia (left ) and hyperalgesia (right ).
Statistical differences were assessed by two-way ANOVA (Time, Genotype
or Treatments) followed by Bonferroni post-hoc test [significant
differences between VEH and ABT-639 group are indicated by asterisks
(*p < 0.05; **p < 0.01; ***p< 0.001)]. Data represent mean ± SEM.